Data from two relevant animal models presented at the 2017 CounterACT meeting by Countervail CEO June 16, 2017 • admin • General News, Military, Pharmaceuticals Read More »
Israeli parent patent for the use of Galantamine and Antimuscarinic Agent For Organophosphorus Poisoning awarded. February 21, 2016 • admin • General News, Military, Pharmaceuticals Read More »
Countervail receives additional $845,000 SBIR Fast Track Phase II grant award for continued development of AverTox® (galantamine) for pre-exposure administration to protect against soman toxicity. May 29, 2015 • admin • Funding, General News, Military, Pharmaceuticals, Uncategorized Read More »
European patent for the use of galantamine as Method of Treating Organophosphorus Poisoning was granted and registered in Germany, Italy, France, UK, Spain, Turkey, Austria, Poland and Sweden. August 13, 2014 • admin • Agriculture, Military, Pharmaceuticals Read More »
US Parent Patent awarded for use of galantamine as Method of Treating Organophosphorus Poisoning. February 2, 2011 • admin • Agriculture, General News, Military Read More »
Countervail corporation is awarded $346,000 for phase 1 of fast track SBIR Grant from the National Institutes of Health for studies of nerve gas antidote September 12, 2010 • admin • Grants, Military Read More »
Master License Agreement Signed with University of Maryland Baltimore for the use of galantamine as a treatment for organophosphate poisoning July 12, 2007 • admin • Military, Pharmaceuticals Read More »
